Benefits of Switch from Oral to Subcutaneous Route on Adherence to Methotrexate in Patients with Rheumatoid Arthritis in Real Life Setting
| Autor: | Sonia Tropé, Yann Fardini, Pierre Clerson, Eric Senbel, Agnès Courbeyrette, Hélène Herman-Demars, Elena Zinovieva, René-Marc Flipo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
rheumatoid arthritis
medicine.medical_specialty Medicine (miscellaneous) Medication adherence compliance methotrexate 03 medical and health sciences oral 0302 clinical medicine Rheumatic Arthritis Quality of life Internal medicine 050602 political science & public administration medicine In real life In patient 030212 general & internal medicine skin and connective tissue diseases Pharmacology Toxicology and Pharmaceutics (miscellaneous) Original Research business.industry Health Policy 05 social sciences medicine.disease switch 0506 political science Subcutaneous route Patient Preference and Adherence Rheumatoid arthritis Methotrexate subcutaneous business Social Sciences (miscellaneous) medicine.drug |
| Zdroj: | Patient preference and adherence |
| ISSN: | 1177-889X |
| Popis: | Eric Senbel,1 Sonia Tropé,2 Hélène Herman-Demars,3 Elena Zinovieva,3 Agnès Courbeyrette,3 Pierre Clerson,4 Yann Fardini,4 René-Marc Flipo5 1Rheumatology Office, Marseille, France; 2French National Patient Organization Against Rheumatoid Arthritis (ANDAR), Montpellier, France; 3Medical Department, Nordic Pharma, Paris, France; 4Soladis Clinical Studies, Roubaix, France; 5University of Lille, Rheumatology Department, Hôpital Roger Salengro, Lille, FranceCorrespondence: Yann FardiniSoladis Clinical Studies, 15 Boulevard Du Général Leclerc, Roubaix, 59100, FranceTel +33 6 46 32 95 85Fax +33 3 28 09 94 76Email yfardini@soladis.frPurpose: The purpose of the APRIM study (for Adherence Polyarthrite Rhumatoïde Injection Methotrexate) was to investigate the change in treatment adherence of patients with rheumatic arthritis (RA) who switched from oral to subcutaneous methotrexate (MTX).Patients and Methods: Prospective, observational study in RA patients treated with MTX and switching from oral to subcutaneous (SC) route in real-life conditions. Data on motivations for switch, disease activity (DAS28-CRP), quality of life (AISM-2 SF), disability (HAQ-DI), and adherence to MTX were collected at inclusion (M0) and 6 months later (M6). Adherence was assessed by the 8-item Morisky Medication Adherence Scale (MMAS-8) and defined as high (MMAS-8 = 8), medium (MMAS-8 = 6 or ≤ 8) or low (MMAS-8 < 6). The primary evaluation criterion was the proportion of patients who maintained strong adherence or improved adherence by at least one category (from low to medium or strong or from medium to strong) between M0 and M6.Results: The analysis involved 207 patients (age 60.4± 12.7 years, 75.2% females). 6.7% were in remission and 15.5% had low disease activity (LDA) at baseline. 58.5% reached the primary criterion and strong adherence rate increased from 42.0% to 50.7%. Change of route was combined with increased MTX dose in 34.8% of patients. Switch to SC route increased the proportion of patients with remission or LDA from 22.8% to 52.9% and increased quality of life even in patients with unchanged MTX dose.Conclusion: Overall, change from oral to SC route improved adherence to MTX, RA control and quality of life independently of change in MTX dose.Keywords: rheumatoid arthritis, methotrexate, oral, subcutaneous, compliance, switch |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |